Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 06:20PM GMT
Release Date Price: €27.22 (+0.28%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. So thanks, everyone, for joining us this morning at the Goldman Sachs Global Healthcare Conference. Really pleased to be joined by the team at Arrowhead Pharmaceuticals, giving us an update on where things are, where things are headed for their RNAi platform.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

So let's start at the beginning of that level. How should we think about Arrowhead's RNAi approach and how it's differentiated versus peers in the landscape?

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Sure. So thanks for having us, Madhu, and thanks to everybody, the Goldman team. So our Arrowhead's RNAi platform, we call it TRiM or targeted RNAi molecules. And the idea behind TRiM is that these are simple conjugates. So they're essentially regardless of if we're going to liver tissue or outside the liver. They're essentially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot